改造RA16的DNA四面体:在非小细胞肺癌中进行向的输送和抑制
Kunyao Xu1,2,3, Hao Wang1, Yongping Jiang2,3
1Beijing University of Chemical Technology, Beijing 100029, China.
ACS applied bio materials
|May 14, 2025
概括
研究人员开发了新的RA16功能化DNA纳米材料,以改善非小细胞肺癌 (NSCLC) 治疗. 这些稳定的纳米粒子增强了药物输送,并显著提高了治疗疗效,为NSCLC患者提供了一个有前途的新治疗平台.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 在瘤学瘤学.
背景情况:
- 肺癌,特别是非小细胞肺癌 (NSCLC),存活率很低,需要创新的治疗策略.
- RNA吸收酶RA16对NSCLC向有前途,但体内稳定性不佳,限制了其临床使用.
研究的目的:
- 开发和评估RA16功能化的DNA纳米材料,用于增强NSCLC向治疗.
- 为了改善RA16合体的稳定性和药物载荷能力,用于临床应用.
主要方法:
- 制造RA16功能化的四面体DNA (TD) 纳米结构,以提高稳定性和药物输送.
- 在实验室中对RA16-TD纳米粒子进行生物相容性,稳定性和药物加载效率的表征.
- 在H460异种移植小鼠模型中的体内评估,以评估装载Epirubicin的RA16-TD的瘤积累和治疗疗效.
主要成果:
- RA16-TD纳米粒子表现出极好的生物相容性,稳定性和高药物载荷能力.
- 与自由的RA16.16相比,RA16-TD显著增强了细胞结合和内部化 (10倍).
- 在体内研究显示,与对照组相比,Epirubicin-loaded RA16-TD的瘤积累率是RA16-TD的2.43倍,瘤抑制率更高 (77.8%).
结论:
- RA16功能化的DNA纳米材料代表了针对性NSCLC治疗的稳定和有效的平台.
- 这种纳米药物输送系统克服了自由体的局限性,改善了治疗结果.
- 开发的平台具有很大的潜力,可以在NSCLC治疗中推进临床应用.
更多相关视频
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
9.0K
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K